TNYA:NASDAQTenaya Therapeutics, Inc. Analysis

Tenaya Therapeutics (TNYA) is trading at $0.74, barely above its computed support of $0.72 and well below the 20‑day SMA of $0.816, indicating limited upside on the short side of the chart. The RSI sits at 41, suggesting the stock is not yet oversold, while the MACD histogram is negative and the signal line is bearish, reinforcing a neutral‑to‑slightly bearish near‑term momentum. Volatility is extreme at 53.6% over the past 30 days and beta is high at 2.37, reflecting a highly responsive price to market swings and a historic max drawdown of roughly 74%.
Fundamentally, the company is cash‑rich ($80.9M) but burdened by a $10.1M debt load and negative earnings (PE -1.79, trailing EPS -$0.44). Analyst consensus is a “strong buy” with a median target of $3.00, implying a potential upside of over 300% from current levels. Recent material news includes a research collaboration with Alnylam Pharmaceuticals and the appointment of a new CFO, both of which could accelerate the development of its gene‑therapy pipeline and improve execution risk.